Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
Teeru Bihani(AstraZeneca (United States)), Celina M. D’Cruz(AstraZeneca (United States))
Cited by 57
Related Papers
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
|Clinical Cancer Research|2015|80
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
|Breast Cancer Research|2019|77